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We studied the expression of polycomb group (PcG) protein BMI-1 in a large population-based patient series of endometrial
carcinomas in relation to clinical and molecular phenotype. Also, 57 fresh frozen endometrial carcinomas were studied for the
relationship between BMI-1 protein expression, BMI-1 mRNA level, and activation of an 11-gene signature reported to represent a
BMI-1-driven pathway. BMI-1 protein expression was significantly weaker in tumours with vascular invasion (Po0.0001), deep
myometrial infiltration (P¼0.004), and loss of oestrogen receptor (ER) (Po0.0001) and progesterone receptors (PR) (P¼0.03).
Low BMI-1 protein expression was highly associated with low BMI-1 mRNA expression (P¼0.002), and similarly low BMI-1 mRNA
expression correlated significantly with vascular invasion, ER and PR loss, and histologic grade 3. In contrast, activation of the reported
11-gene signature, supposed to represent a BMI-1-driven pathway, correlated with low mRNA expression of BMI-1 (Po0.001),
hormone receptor loss, presence of vascular invasion, and poor prognosis. We conclude that BMI-1 protein and mRNA expression
are significantly correlated and that BMI-1 expression is inversely associated with activation of the 11-gene signature. Loss of BMI-1
seems to be associated with an aggressive phenotype in endometrial carcinomas.
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Endometrial cancer is one of the most common malignant
tumours of the female genital tract and its incidence is increasing
in developed countries (WHO, 2003). The molecular pathogenesis
of endometrial carcinoma remains poorly understood, but it is
widely believed that a common feature of human cancer cells is
their ability to bypass control mechanisms restricting prolifera-
tion, apoptosis, angiogenesis, invasion, and metastases (Hanahan
and Weinberg, 2000; Lax, 2004; Ryan et al, 2005; Prat et al, 2007).
Over the years, several reports on endometrial cancer and
prognostic factors have been published, and the impact of age,
histologic type and grade, Federation of Gynecology and Obstetrics
(FIGO) stage, ploidy, and hormone receptor status is well
established (Amant et al, 2005).
BMI-1 is a member of the polycomb group (PcG) of genes
that are important transcriptional regulators by the formation
of PcG bodies and chromatin remodelling (Shao et al, 1999).
BMI-1 acts through epigenetic silencing by organising the
chromatin into an inaccessible structure that cannot bind
transcription factors, and it may, in fact, also act by repressing
cyclin-dependent kinase inhibitors p16/INK4a and p14/ARF
(Jacobs et al, 1999; Jacobs and van Lohuizen, 2002; Pasini et al,
2004; Liu et al, 2006).
Recent studies have promoted BMI-1 as a stem cell marker that
regulates self-renewal in haematopoietic and leukaemic stem cells
(Lessard and Sauvageau, 2003; Raaphorst, 2003). Elevated expres-
sion of human BMI-1 has also been reported in multiple cancer
samples by immunohistochemistry or mRNA analysis for oral
cancers (Kang et al, 2007), lung cancers (Vonlanthen et al, 2001;
Breuer et al, 2004), lymphomas (Dukers et al, 2004; Raaphorst
et al, 2004), and breast cancer (Kim et al, 2004; Silva et al, 2006) as
well as in cancer cell lines (Satijn et al., 1997; Satijn and Otte,
1999), although the exact function is not known.
Global gene expression profiling can be used to identify
molecular signatures associated with activation of certain
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soncogenic pathways (Huang et al, 2003). Glinsky et al (2005)
described the prognostic impact of an 11-gene signature
displaying a stem cell-resembling expression profile. Their data
indicate the presence of a conserved BMI-1-driven pathway,
which is similarly engaged in normal stem cells and in a series of
highly malignant human cancers arising from a wide range of
organs. Steele et al (2006) used SEREX technology and
proved widespread overexpression of BMI-1 protein in different
tumour types. The role of BMI-1 in endometrial carcinomas is
unknown.
On the basis of this background, we have investigated the
expression of BMI-1 in endometrial carcinomas in relation to
histopathologic features, markers of cell-cycle regulation, and
hormone receptors, as well as patient outcome. In particular, we
wanted to investigate the relationship between BMI-1 protein
expression, BMI-1 mRNA levels, and activation of the 11-gene
signature reported to represent a BMI-1-driven pathway (Glinsky
et al, 2005) in relation to the clinical and molecular phenotype.
MATERIALS AND METHODS
Two independent population-based patient series have been
studied for protein expression of BMI-1 and the prognostic
relevance of traditional and newly described markers. In a
retrospectively collected patient series, all 316 patients diagnosed
with endometrial carcinoma in Hordaland County of Western
Norway from 1981 to 1990 were studied (patient series 1). Paraffin
blocks from the primary tumour were available in 286 cases (96%).
In this particular study, 264 cases had sufficient material in the
tissue microarray (TMA) blocks for the immunohistochemical
study of BMI-1 expression using two different antibodies. Data
from previously studied tumour markers, such as vascular
invasion, growth pattern, depth of myometrial infiltration, tumour
cell proliferation, DNA index, oestrogen receptor (ER), progester-
one receptor (PR), HER-2/neu, p53, and p16 expression, were
available for comparisons (Salvesen et al, 1999, 2000; Stefansson
et al, 2004b). The patient material and treatment protocol of this
series are described in detail elsewhere (Salvesen et al, 1999;
Engelsen et al, 2006).
The follow-up data were collected from the medical records and
correspondence with the primary physicians. The median follow-
up period for the survivors was 9 years (range 5–15 years). None
of the patients were lost due to insufficient follow-up information.
Among the 117 patients who died during the follow-up period, 70
died from endometrial carcinoma, whereas 47 died from other
causes. The follow-up data were cross-checked with information
from the Cancer Registry of Norway, which is matched against the
Register of Deaths of Statistics Norway. The last date of follow-up
was 30 June 1996.
To further explore the BMI-1 mRNA and protein expression,
and the reported 11-gene signature for a BMI-1-driven pathway,
fresh endometrial carcinoma tissue was collected prospectively
from 57 randomly selected patients from a population-based tissue
bank collected in the period 2001–2004 (patient series 2).
Clinicopathologic data such as age at the time of diagnosis,
International FIGO stage, according to the 1988 criteria, histologic
type and histologic grade, vascular invasion, myometrial
infiltration, presence of lymph node metastases, and treatment
and survival were recorded. Patients were followed from the time
of primary surgery until June 2007 or until death. Median follow-
up time for survivors was 3.6 years (range 0.8–5.5 years). To
elucidate potential selection bias for the prospectively collected
patient series, the traditional clinicopathologic variables were
compared to the corresponding data for the initial complete
population-based series from 1981 to 1990, and no significant
differences in patient characteristics were detected (Supplementary
Table 1).
Tissue microarray
Tumour specimens from both patient series studied were mounted
in TMA as previously described and validated in several studies
(Hoos et al, 2001; Straume and Akslen, 2002; Stefansson et al,
2004a). Tissue microarray construction was made by identifying
the area of highest tumour grade on H&E-stained slides, followed
by punching out three tissue cylinders from the selected areas of
the donor block and then mounted into a recipient paraffin block
using a custom-made precision instrument (Beecher Instruments,
Silver Spring, MD, USA).
Immunohistochemistry
The immunohistochemical staining was performed on thin TMA
sections (5mm) of paraffin-embedded tissue. The slides were
dewaxed with xylene/ethanol before microwave antigen retrieval
for 10min at 750W and 15min at 350W in TE 9 buffer (pH 9). The
slides were incubated overnight at 41C with a monoclonal BMI-1
antibody (clone F6; Upstate, Lake Placid, NY, USA) diluted 1:800.
Slides incubated with Mouse IgG1 diluted 1:800 were used as
negative controls. Samples of breast and prostate cancers with
known BMI-1 positivity were used as positive controls. The
staining was performed using the EnVision-labelled polymer
method, with a commercial kit (Dako Cytomation, Copenhagen,
Denmark), with 3-amino-9-ethylcarbazole (AEC) peroxidase as
substrate before brief counterstaining with Mayer’s haematoxylin.
The TMA sections were also stained with a well-described non-
commercial monoclonal anti-BMI-1 antibody (Breuer et al, 2004;
Dukers et al, 2004). After pretreatment and antigen retrieval as
described above, the slides were incubated for 60min at room
temperature with the undiluted monoclonal antibody (6C9) before
completion of the staining procedure using the Catalyzed Signal
Amplification System (Dako Cytomation) in line with the
instructions from the manufacturer.
The arrays were scored blinded for clinical information and
results from the other markers studied, and there was good
correlation between the two investigated antibodies (Pearson’s
correlation coefficient 0.64, Po0.0001).
Evaluation of staining
The immunohistochemical staining of BMI-1 showed a predomi-
nantly nuclear staining pattern. The staining was recorded using a
semiquantitative and subjective grading, considering both the
intensity of staining and the proportion of tumour cells showing
unequivocal positive reaction. A staining index (SI) was calculated
as a product of staining intensity (0–3) and area of positive
tumour cell nuclei (1¼o10%, 2¼10–50%, 3¼450%) (Aas et al,
1996; Straume and Akslen, 1997). Evaluation of the cases was
carried out blinded for patient characteristics and outcome. In
subsequent statistical analyses, the cut-off was based on the
median value for the SI, after considering the frequency
distribution curve and the size of subgroups.
Microarray analysis
Surgically removed tumour biopsies were quick frozen and
subsequently ground to powder in a mortar under liquid N2.
Total RNA was extracted according to standard protocols
(Invitrogen (Carlsbad, CA, USA) Trizol LS protocol and Qiagen
(Hilden, Germany) RNeasy Mini Kit protocol). Assessment of
quality and yield of total RNA, extraction of poly(A) RNA, and
preparation of Cy-labelled hybridisation targets have been
described in detail (Petersen et al, 2007). Approximately 500ng
each of endometrial Cy
3-labelled aminoallyl-cRNA and Stratagene
Universal RNA Cy
5-labelled aminoallyl-cRNA at a specific labelling
of about 100pmol Cy per mg cRNA were combined, fragmented,
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sand hybridised with the Agilent 21k (batch 1) and 22k human
oligonucleotide microarrays (batch 2) according to the manufac-
turer’s protocol (Agilent Technologies, Santa Clara, CA, USA).
After hybridisation at 601C for 17h, the stringent wash was done in
50ml 0.1  SSC at 351C for 10min followed by three quick washes
in 0.1  SSC at room temperature. The oligonucleotide micro-
arrays were scanned and features automatically extracted,
recorded, and analysed using the Agilent Microarray Scanner
Bundle.
mRNA was extracted from surgically dissected and fresh frozen
primary tumours from clinically well-defined endometrial carci-
nomas. All primary tumour specimens were examined histologi-
cally to ensure at least 50% neoplastic tissue, but the majority of
the samples showed at least 80% neoplastic tissue.
Batch adjustment
As the samples were hybridised in two rounds on two different
array print batches and initial clustering of the samples
indicated batch effects (data not shown), the data were adjusted
to minimise this effect. A representative subset of samples
with similar biology, which was based on a selection of external
variables, was selected from each batch and formed the basis for
batch adjustment. Then for each gene, the expression levels
of each sample batch was adjusted such that the mean
expression level of the representative subset was set to 0 (Lapointe
et al, 2004).
Real-time quantitative PCR estimation of mRNA
mRNA expression for BMI-1 and selected markers, such as ERa,
PR, p16, p53, and HER-2/neu, were validated by quantitative
PCR (qPCR) using the TaqMans Low Density Array (TLDA)
technique (Rostad et al, 2007). TaqMan Low Density Arrays are
customisable, 384-well microfluidic cards for real-time qPCR
(Applied Biosystems, Foster City, CA, USA). TaqMan Low Density
Array cards were constructed with two control genes (GAPDH and
ACTB (b-actin), and the selected genes were analysed in duplicate.
Single-stranded cDNA for qPCR analysis was synthesised from
2mg of total RNA using a final concentration of 5mM random
hexamer primers, pd (N)6 (GE Healthcare Life Sciences, Uppsala,
Sweden) and M-MLV reverse transcriptase according to Ambion
instructions (Applied Biosciences, Foster City, CA, USA). Com-
plementary DNA corresponding to 40ng of endometrial total RNA
was mixed with TaqMan Universal buffer and added to each TLDA
loading well as recommended (Applied Biosystems). The PCR
reaction was run at 501C for 2min, 951C for 10min, and 40 cycles
at 951C for 15s and 601C for 60s. The SDS 2.2 software was used
for data analysis.
Activation of a gene signature for BMI-1-driven pathway
In our microarray data set, 9 out of 11 genes in the BMI-1-
associated signature reported by Glinsky et al (2005) were
identified and used to see if the BMI-1 signature activation was
related to the phenotype of endometrial carcinomas. The BMI-1
activation signature contains eight upregulated genes, GBX2,
MKI67, CCNB1, BUB1, KNTC2, USP22, HCFC1, and RNF2, and
three downregulated genes, ANK3, FGFR2, and CES1, of which all
but KNTC2 and USP22 were available in the present data set
(Figure 4). Expression data were normalised by subtracting the
mean expression of each gene and then dividing by the s.d. The
signature was then evaluated by computing the sum of normalised
expression values for the upregulated genes minus the sum of the
downregulated genes.
Validation of gene signature for BMI-1-driven pathway in
external data set
Publicly available gene expression data corresponding to tumours
resected from uterine tissue were obtained from the TGEN
expression profiling for oncology (http://expo.intgen.org/geo/
home.do). GEO accession numbers for these tumours are listed
in Supplementary Table 2. One hundred and four of the uterine
tumours had information regarding histologic subtype available,
91 endometrioid and 13 non-endometrioid tumours, whereas 68
tumours had information regarding histologic grade available, 39
grade 1/2 tumours, and 29 grade 3 tumours. Survival data were not
available for these patients. All 11 genes in the BMI-1-associated
signature reported by Glinsky et al (2005) were identified in this
data set and were used to see if our finding that BMI-1 signature
activation was related to the phenotype of endometrial carcinomas
could be validated in external data.
Statistics
Analyses were performed by the statistical software package SPSS
14.0. Associations between different variables were assessed by
the Mann–Whitney test, Pearson’s w
2 test, and linear regression.
Univariate analyses of time to recurrence (recurrence free survival)
and death due to endometrial carcinoma (disease-specific survival)
were performed using the Kaplan–Meier method. Differences in
survival between categories were estimated by the log-rank
(Mantel Cox) test. The cut-off was based on the median value
for the SI and mRNA expression levels, after considering the
frequency distribution curve and the size of the subgroups. The
tumour samples were analysed for expression level for 9 out of 11
genes in the BMI-1 activation signature available in the data set
using the J-Express tool (Dysvik and Jonassen, 2001). Before
clustering, the expression profiles of each gene were centred by
subtracting the mean over all samples. The genes were subjected to
hierarchical clustering using average linkage (WPGMA) and
Pearson’s correlation as similarity measures. The resulting
unsupervised clustering reveals two main clusters of samples,
which are referred to as cluster 1 and cluster 2 (Figure 4).
RESULTS
Immunohistochemical staining for BMI-1
One hundred and forty-four (55%) of 264 patients in the
retrospective population-based patient series showed strong
nuclear staining in 450% of the tumour cells. BMI-1 expression
(Clone F6) was significantly lower in tumours with the presence of
vascular invasion (Po0.0001) and deep myometrial infiltration
(P¼0.004) (Table 1). Low BMI-1 expression was also significantly
associated with the loss of immunohistochemical staining for ER
(Po0.0001) and PR (P¼0.03) (Table 1) and for tumours with
diffusely infiltrative growth pattern when compared to those with
pushing border (P¼0.01) (Stefansson et al, 2006). When analysing
the non-commercial BMI-1 antibody (Breuer et al, 2004; Dukers
et al, 2004), similar results were obtained (data not shown). For the
other clinicopathologic variables (FIGO stage, histologic subtype,
and histologic grade), we found no significant associations.
mRNA estimation of BMI-1 by qPCR
mRNA expression of BMI-1 estimated by microarray and qPCR
was significantly correlated (r¼0.56 (Pearson’s); Po0.001, Sup-
plementary Figure 1). Low immunohistochemical staining for
BMI-1 was significantly associated with low mRNA BMI-1
expression (P¼0.002, Figure 1A). We found a highly significant
association between the presence of vascular invasion and low
BMI-1 mRNA expression (P¼0.005, Figure 1B, Table 2). Low
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IB Engelsen et al
1664
British Journal of Cancer (2008) 98(10), 1662–1669 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smRNA expression was also associated with high histologic grade
(P¼0.02), whereas the association with non-endometrioid histo-
logic subtype was of borderline significance (P¼0.07). There was
no association with FIGO stage or myometrial infiltration (Table 2).
Owing to the identified correlations between BMI-1 expression and
steroid hormones in the immunohistochemical studies, we also
investigated the correlation between mRNA expression for BMI-1
and ERa/PR. A highly significant correlation between BMI-1 and
ERa (r¼0.39; P¼0.003) and PR (r¼0.36; P¼0.007) was
confirmed (Figure 2A and B).
Activation of a gene signature for BMI-1-driven pathway
The endometrial carcinomas in the present data set were then
investigated for activation of a BMI-1-driven signature reported by
Glinsky et al (2005). Nine out of 11 genes were available in our
microarray data sets, and the activation level of this signature was
inversely correlated with mRNA expression of BMI-1 (r¼ 0.58;
Po0.001, Figure 3), ERa (r¼ 0.62; Po0.001), and PR (r¼ 0.64;
Po0.001) (Figure 2C and D). BMI-1 activation signature was
significantly correlated to non-endometrioid histologic subtype
(P¼0.001), high histologic grade (grade 3 vs 1/2) (P¼0.001),
vascular invasion (P¼0.04), and poor patient prognosis
(P¼0.009) (Table 3 and Figure 4C and D). When correlating
histologic subtype and grade to activation of the BMI-1-driven
signature in external gene expression data, activation of this
signature confirmed it to be significantly correlated to
non-endometrioid histologic subtype (P¼0.02) and high histologic
grade (grade 3) (P¼0.001).
Survival analyses
We analysed both patient series for a survival impact of BMI-1
expression in univariate survival analysis. Neither of the two
antibodies used for immunohistochemical staining nor the mRNA
expression was associated with patient survival. In contrast,
unsupervised clustering based on 9 out of 11 genes in the BMI-1
signature revealed two distinct clusters, and the cluster with
activation of the BMI-1-related signature was highly significantly
associated with poor prognosis (P¼0.009) (Figure 4C).
DISCUSSION
This is, to the best of our knowledge, the first study on BMI-1
expression in endometrial carcinomas. Further, this is the first
study to relate BMI-1 protein expression to BMI-1 mRNA
expression and the level of activation for the previously reported
BMI-1 signature in the same tumours. High BMI-1 expression,
estimated both by immunohistochemical staining and by qPCR for
mRNA levels, was seen in a subgroup of endometrial carcinomas.
This appears to be in line with other studies showing high BMI-1
expression in a range of malignant tumours, such as oral cancer,
lung cancer, Hodgkin’s lymphoma, breast cancer, hepatocellular
cancer and prostate cancer (Vonlanthen et al, 2001; Breuer et al,
2004; Dukers et al, 2004; Glinsky et al, 2005; Shi et al, 2005; Steele
et al, 2006; Kang et al, 2007; Silva et al, 2007). Also, the
immunohistochemical expression pattern in endometrial tumours
was concordant with the mRNA levels for BMI-1, indicating the
relevance of BMI-1 protein in this tumour type.
The importance of BMI-1 for tumour progression in endo-
metrial carcinomas is unknown. We find that the loss of BMI-1
protein and loss of mRNA expression are highly significantly
correlated. The correlation between low expression of BMI-1
protein and histological grade 3 and non-endometrioid subtype is
weaker and not significant as compared with the significant or
borderline significant correlation for low mRNA expression and
these two factors. There is, however, a pattern in the same
direction for BMI-1 protein expression. BMI-1 mRNA expression
is estimated as a continuous variable, and this may increase the
ability to detect differences. We find that the low immunohisto-
chemical expression and mRNA level of BMI-1 was significantly
correlated to the presence of vascular invasion, suggesting a more
aggressive phenotype. An association between BMI-1 and vascular
involvement has not been previously reported. Further, in our
studies, low BMI-1 protein and mRNA expression were signifi-
cantly associated with low expression of the steroid receptors ER
and PR. This has previously been reported for breast cancer in
some studies (Kim et al, 2004; Arnes et al, 2008), but not in others
(Silva et al, 2007). Still, this could indicate a potential link between
BMI-1 and hormone receptor status. Paradoxically, high expres-
sion of BMI-1 was significantly associated with positive ER status
and with the presence of lymph node metastasis in one study (Kim
et al, 2004), indicating a diverse role of BMI-1. Overexpression of
BMI-1 has shown a prognostic impact on survival only in some
studies but not all (Silva et al, 2006; Song et al, 2006).
In our study, BMI-1 did not show any correlation with
downstream target p16, indicating suppression. The lack of
association between BMI-1 and p16 expression has also been
reported for breast cancer (Silva et al, 2006), lung cancer (Breuer
et al, 2005), and Hodgkin’s lymphoma (Dukers et al, 2004),
whereas in oral cancer (Kang et al, 2007) and nasopharyngeal
cancer (Song et al, 2006), BMI-1 has been indicated to act through
p16 to regulate cellular proliferation. Liu et al (2006) recently
showed that in cell line studies for different tissues that in both
Table 1 BMI-1 protein expression in tumours related to clinicopatho-
logic variables and biomarkers in a population-based study of endometrial
carcinomas
a
BMI-1 expression
b
Low High
Variable n (%) n (%) P-value
FIGO stage 0.39
I/II 118 (56) 94 (44)
III/IV 25 (49) 26 (51)
Histologic subtype 0.43
Endometrioid 127 (53) 111 (47)
Non-endometrioid 16 (62) 10 (38)
Histologic grade (FIGO) 0.38
Grades 1–2 112 (53) 100 (47)
Grade 3 31 (60) 21 (40)
Vascular invasion o0.0001
Not present 74 (44) 93 (56)
Present
c 69 (71) 28 (29)
Myometrial infiltration 0.004
o50% 56 (49) 58 (51)
X50% 50 (70) 21 (30)
ER 0.001
Low expression 44 (77) 13 (23)
High expression 85 (51) 82 (49)
PR 0.03
Low expression 46 (69) 21 (31)
High expression 84 (53) 74 (47)
ER¼estrogen receptor; FIGO¼Federation of Gynecology and Obstetrics;
PR¼progesterone receptor.
aTwo hundred and sixty-four cases with evaluable
staining for BMI-1 (Upstate), missing data for FIGO stage in 1 case, depth of
myometrial infiltration in 79 cases, for ER in 40 cases, and for PR in 39 cases.
bMedian
used as cut-off value.
cVascular invasion of tumour cells detected in X2 vessels.
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snormal and cancer cells, the loss of BMI-1 led to the upregulation
of p16, but with no significant effect on the level of telomerase gene
expression. This suggests that other BMI-1 cooperative factors may
be involved in the BMI-1-dependent cancer-specific growth
retardation.
The reported signature by Glinsky et al (2005) has been assumed
to represent an activated BMI-1-driven pathway, and it has been
linked to poor survival for a range of cancers. We found a
significant association between the activation of this Glinsky
signature and non-endometrioid histologic subtype, histologic
grade 3, vascular invasion, and survival in line with what has
been reported for other cancer types (Glinsky et al, 2005). The
correlation with histologic subtype and grade was also validated in
external data. Thus, our findings confirm an association between
the activated 11-gene signature and an aggressive phenotype for
endometrial cancer, and this has not been previously shown for
this cancer type.
In contrast, we found that low BMI-1 expression was associated
with high-risk factors such as histologic grade 3, vascular invasion,
and loss of hormone receptors. It appears to be counter-intuitive
that expression levels for BMI-1 by mRNA is inversely correlated
to the expression level for the Glinsky signature reported to
represent a BMI-1-driven pathway. The finding that low BMI-1
expression is associated with several markers of poor prognosis is
fairly consistent both for protein and for mRNA expression. A
series of complex signalling pathways may influence the expres-
sion level of the Glinsky signature. Still, on the basis of our results,
this regulation seems to be more complex than by a direct effect
through BMI-1 mRNA expression. The critical factors driving the
expression level for this signature are not known and have not
previously been studied for endometrial carcinomas. Our findings
may suggest that this signature does not represent only a BMI-1-
driven pathway for endometrial carcinomas.
Although Glinsky et al found low BMI-1 mRNA expression to be
associated with less aggressive tumours of prostate cancer, a
finding that is supported by others in studies of non-small-cell
lung cancer and breast carcinomas (Vonlanthen et al, 2001;
Raaphorst et al, 2003), we found that low BMI-1 expression is
associated with markers of a more aggressive phenotype in
endometrial cancer, even though no significant prognostic impact
of BMI-1 expression is seen.
2.00
0.00
–2.00
B
M
I
-
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
BMI-1 protein expression
Low High Not present Present
Vascular invasion
Negative BMI-1 expression
Positive BMI-1 expression
2.00
0.00
–2.00 P=0.005 P=0.002
Figure 1 Box plot illustrating correlation between BMI-1 protein expression and mRNA BMI-1 expression. Among samples with low BMI-1 protein
expression, there is a highly significantly lower level of BMI-1 mRNA expression (A). Cases with vascular invasion show significantly lower level of BMI-1
mRNA expression (B). Low BMI-1 expression was seen in 25 (44%) samples compared with high expression in 32 (56%) samples. Examples of high
immunohistochemical BMI-1 expression are illustrated in panel C and low expression in panel D.
Table 2 BMI-1 mRNA expression estimated by qPCR in 57 prospec-
tively collected, fresh-frozen endometrial cancers in relation to clinico-
pathologic variables
Variable n Median P-value
FIGO stage
I/II 48  0.09 0.19
III/IV 9  0.33
Histologic type
Endometrioid 51  0.11 0.07
Non-endometrioid 6  0.65
Histologic grade
Grade 1/2 44  0.07 0.02
Grade 3 13  0.66
Vascular invasion
Not present 35 0.15 0.005
Present
a 22  0.43
Myometrial infiltration
o50% 30  0.09 0.76
X50% 27  0.20
FIGO¼Federation of Gynecology and Obstetrics; qPCR¼quantitative PCR.
aVascular invasion detected in X2 vessels.
BMI-1 is associated with aggressive endometrial cancer
IB Engelsen et al
1666
British Journal of Cancer (2008) 98(10), 1662–1669 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sGlinsky et al claim that the signature represents a ‘stem’-like
cellular state, required for self-renewal. However, some of the
genes, such as MKI67, CCNB1, and BUB1, have also been reported
to come up in standard proliferation signatures (Moreno-Bueno
et al, 2003) and signatures for chromosomal instability (Carter
et al, 2006), which may also explain the prognostic influence of this
reported signature. All of these biologic processes may be closely
related, and it may not be possible to separate them, as BMI-1 has
also been found to be important for chromatin remodelling
(Shao et al, 1999) and may affect proliferation by repressing the
cyclin-dependent kinase inhibitors p16/INK4a and p14/ARF
(Jacobs et al, 1999; Jacobs and van Lohuizen, 2002; Pasini et al,
2004; Liu et al, 2006).
In conclusion, we demonstrate for the first time that loss of
BMI-1 expression is significantly correlated with vascular invasion
and loss of hormone receptors in endometrial carcinomas. This
could indicate a protective role of the BMI-1 protein in this tumour
type. BMI-1 mRNA expression is inversely correlated to the level of
activation by the reported BMI-1 activation signature, supposed to
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Figure 2 Scatter plot of mRNA expression by qPCR for oestrogen receptor (A) and progesterone receptor (B) in relation to BMI-1 mRNA expression
(qPCR) and mRNA expression of the 11-gene BMI-1 signature (C and D). A regression line is drawn to illustrate the relationship.
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Figure 3 Scatter plot of BMI-1 mRNA expression by qPCR and the level
of the reported 11-gene BMI-1 signature. A regression line is drawn to
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Table 3 BMI-1 11-gene signature activation based on mRNA expression
by microarray data in 57 prospectively collected fresh-frozen endometrial
cancer tumours in relation to clinicopathologic variables
Variable n Median P-value
FIGO stage
I/II 48  0.04 0.1
III/IV 9 0.27
Histologic type
Endometrioid 51  0.06 0.01
Non-endometrioid 6 0.58
Histologic grade
Grade 1/2 44  0.20 0.001
Grade 3 13 0.56
Vascular invasion
Not present 35  0.23 0.04
Present
a 22  0.13
Myometrial infiltration
o50% 30  0.02 0.28
X50% 27  0.14
FIGO¼Federation of Gynecology and Obstetrics.
aVascular invasion detected in X2
vessels.
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srepresent a BMI-10driven pathway. We then show that activation
of this signature is associated with an aggressive phenotype and
survival in endometrial carcinomas. Our findings justify further
studies to validate the role of BMI-1 in endometrial carcinomas.
Also, studies of the possible value of BMI-1 in novel treatment
strategies for this disease are needed.
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